GCN2(Phospho Thr899) Polyclonal Antibody

This gene encodes a member of a family of kinases that phosphorylate the alpha subunit of eukaryotic translation initiation factor-2 (EIF2), resulting in the downregulaton of protein synthesis. The encoded protein responds to amino acid deprivation by binding uncharged transfer RNAs. It may also be activated by glucose deprivation and viral infection. Mutations in this gene have been found in individuals suffering from autosomal recessive pulmonary venoocclusive-disease-2.

The GCN2(Phospho Thr899) Polyclonal Antibody is a highly specific and sensitive tool designed for the detection and quantification of GCN2 protein phosphorylated at threonine 899 residue. This antibody is produced using advanced immunization techniques and exhibits exceptional affinity and selectivity towards the phosphorylated form of GCN2.

The GCN2 protein plays a crucial role in the regulation of cellular stress responses and the integrated stress response pathway. Phosphorylation of GCN2 at threonine 899 is a key event in the activation of its kinase activity, leading to downstream signaling cascades involved in the control of protein synthesis and cellular adaptation to stress conditions.

This polyclonal antibody has been rigorously validated for its specificity and sensitivity through various experimental approaches, including Western blotting, immunoprecipitation, and immunofluorescence. It has been shown to specifically recognize the phosphorylated form of GCN2 at threonine 899, while exhibiting minimal cross-reactivity with non-phosphorylated GCN2 or other related proteins.

The GCN2(Phospho Thr899) Polyclonal Antibody is supplied as a ready-to-use solution, ensuring convenience and ease of use. It is suitable for a wide range of applications, including basic research, drug discovery, and diagnostic development. With its high specificity and sensitivity, this antibody enables accurate and reliable detection of phosphorylated GCN2, facilitating a deeper understanding of cellular stress responses and the development of targeted therapeutic strategies.